scholarly journals The novel incorporation of aromatase inhibitor in hormonal replacement therapy cycles: A randomized clinical trial

Author(s):  
Eman Amin Elgindy ◽  
Amany Ahmed Abdelghany ◽  
Hoda Sibai AbdAlsalam ◽  
Magdy Ibrahim Mostafa
2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Biwen Cheng

Abstract Background Gynecologic anomalies, including uterine agenesis and ovarian dysgenesis, are some of the several differential diagnoses in adolescent females with primary amenorrhea and delayed puberty. Primary ovarian insufficiency is reported in the clinical practice of reproductive endocrinology can be determined by conducting sex hormone tests to evaluate the hypothalamic-pituitary-ovarian axis. However, confirmation of Mullerian agenesis by image modalities can be extremely challenging. Once the diagnosis is established, breakthrough bleeding usually occurs 2 to 3 years after hormonal replacement therapy. Case presentation We report a case of a seventeen year old Taiwanese female, 46 XX karyotype, with ovarian dysgenesis and an initial tentative diagnosis of uterine agenesis who experienced a breakthrough bleeding after a month of hormonal replacement therapy. Conclusions The breakthrough bleeding after a month of estrogen therapy in primary ovarian insufficiency is uncommon, and the diagnosis of the absent uterus can have an extensive psychological impact on patients and their families.


Author(s):  
Lourdes G. Baeza-Perez ◽  
Claudia Calzada-Mendoza ◽  
Maria Elena Hernandez-Campos ◽  
Pedro Lopez-Sanchez ◽  
Liliana Anguiano-Robledo

Sign in / Sign up

Export Citation Format

Share Document